Polycystic Ovarian Syndrome Clinical Trial
Official title:
A Randomized Control Trial to Compare the Euploid Rate of Blastocyst Between the PPOS (Progestin-primed Ovarian Stimulation) Protocol and the Gonadotropin-releasing Hormone (GnRH) Antagonist Protocol in Women With PCOS (Polycystic Ovary Syndrome) Undergoing PGT-A (Preimplantation Genetic Testing for Aneuploidy)
This randomized trial aims to compare the euploid rate of blastocysts between PPOS (progestin-primed ovarian stimulation) and GnRH (gonadotrophin releasing hormone) antagonist protocols in patients with PCOS (polycystic ovary syndrome) undergoing PGT-A (preimplantation genetic testing for aneuploidy). Infertile women with PCOS will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. PPOS group: Women will receive oral MPA (medroxyprogesterone acetate)10mg qd from Day 3 till the day of ovulation trigger. The primary outcome is the euploidy rate of blastocysts.
Status | Not yet recruiting |
Enrollment | 204 |
Est. completion date | December 1, 2026 |
Est. primary completion date | December 1, 2025 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years to 37 Years |
Eligibility | Inclusion Criteria: - Women age between 20 and 37 years. - Women diagnosed with PCOS according to the modified Rotterdam criteria: oligomenorrhea or amenorrhea, together with the presence of =12 antral follicles (=9 mm) and/or ovarian volume >10 mL on transvaginal ultrasonographic scanning, and/or clinical/ biochemical hyperandrogenism. Other causes of hyperandrogenism and ovulation dysfunction-including tumours, congenital adrenal hyperplasia, hyperprolactinaemia and thyroid dysfunction-were excluded Exclusion Criteria: - Presence of a functional ovarian cyst with E2>100 pg/mL - Endometriosis grade 3 or higher - Repeated implantation failure (>=4 embryos replaced or >=2 blastocysts replaced without success) - Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus uni-cornate, bicornate, or duplex); untreated uterine septum, adenomyosis, submucous myoma, or endo-metrial polyp(s) - Women who are indicated and planned to undergo PGT-SR (Preimplantation genetic testing for structural rearrangement) or PGT-M (Preimplantation genetic testing for monogenic disorder), for example, parental abnormal karyo-type or diagnosed with monogenic disease; - Recipient of oocyte donation - Presence of hydrosalpinx which is not surgically treated |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
ShangHai Ji Ai Genetics & IVF Institute |
Begueria R, Garcia D, Vassena R, Rodriguez A. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Hum Reprod. 2019 May 1;34(5):872-880. doi: 10.1093/humrep/dez034. — View Citation
Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN; PCOS/Troglitazone Study Group. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan;91(1):48-53. doi: 10.1210/jc.2005-1329. Epub 2005 Oct 25. — View Citation
Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, Ai A, Shoham Z. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015 Jul;104(1):62-70.e3. doi: 10.1016/j.fertnstert.2015.03.022. Epub 2015 May 5. — View Citation
Lee E, Illingworth P, Wilton L, Chambers GM. The clinical effectiveness of preimplantation genetic diagnosis for aneuploidy in all 24 chromosomes (PGD-A): systematic review. Hum Reprod. 2015 Feb;30(2):473-83. doi: 10.1093/humrep/deu303. Epub 2014 Nov 28. — View Citation
Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update. 2017 Mar 1;23(2):211-220. doi: 10.1093/humupd/dmw047. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | euploidy rate | euploidy rate of blastocysts | 1 month after oocyte retrieval | |
Secondary | live birth rate | deliveries =22 weeks gestation with heartbeat and breath of the first frozen embryo transfer | 1 year after embryo transfer | |
Secondary | cumulative live birth rate | cumulative live birth within 6 months of randomization | 1 year after embryo transfer | |
Secondary | ongoing pregnancy | a viable pregnancy beyond 12 weeks' gestation of the first frozen embryo transfer | 12 weeks' gestation | |
Secondary | number of oocytes retrieved | number of oocytes retrieved | 1 day after oocyte retrieval | |
Secondary | OHSS(ovarian hyperstimulation syndrome) | Moderate or severe ovarian hyperstimulation syndrome.Ovarian hyperstimulation syndrome (OHSS) is diagnosed and classified according to the Royal College of Obstetricians and Gynaecologists guideline.
Green-top guideline No.5. Ovarian hyperstimulation syndrome. https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg5/ (accessed 26 Feb 2016). |
1 month after ovarian stimulation | |
Secondary | birthweight of newborns | birthweight of newborns | 1 year after embryo transfer |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02244567 -
Effect of Metformin Therapy on Serum Under-carboxylated Osteocalcin Levels in Hyperandrogenic Lean Polycystic Ovarian Syndrome Women
|
Phase 1 | |
Completed |
NCT01672801 -
Nimodipine to Prevent LH Surge During Ovulation Induction: Blinded Placebo-controlled RCT
|
N/A | |
Completed |
NCT01653743 -
Trial to Assess the Clinical Efficacy and Safety of MSJ-0011 in Inducing Ovulation in Anovulatory or Oligo-ovulatory Japanese Women
|
Phase 3 | |
Completed |
NCT00579540 -
Compare Effects of Flax Seed Oil, and Fish Oil on Blood Sugar Levels
|
N/A | |
Terminated |
NCT05084274 -
Optimising Preconceptual Health in Subfertile PCOS Patients Using a Lifestyle Modification Program
|
N/A | |
Completed |
NCT03717935 -
Oral Amino Acid Nutrition to Improve Glucose Excursions in PCOS
|
N/A | |
Withdrawn |
NCT01716429 -
Healthy Eating for Reproductive Health: Greenville
|
N/A | |
Active, not recruiting |
NCT02896452 -
Astronaut Vision Issues in a Ground Analog Population: Polycystic Ovary Syndrome
|
||
Recruiting |
NCT05146063 -
LNK in Polycystic Ovary Syndrome With Insulin Resistance
|
||
Recruiting |
NCT06303219 -
Effects of Traditional Moderate Intensity Training and High Intensity Interval Training in Polycystic Ovarian Syndrome
|
N/A | |
Completed |
NCT02869750 -
The Relationship Between Adipokines, Obesity and Insulin Resistance in Women With Polycystic Ovarian Syndrome
|
||
Completed |
NCT01237106 -
In Vitro Maturation (IVM) for Polycystic Ovary Syndrome (PCOS)
|
N/A | |
Completed |
NCT01185704 -
Analysis of Two Therapeutic With Cetrotide® in Polycystic Ovarian (PCO) Women in Assisted Reproductive Technology (ART)
|
Phase 3 | |
Recruiting |
NCT04029805 -
Evaluation of a Combination of a Plant Extract and a Probiotic on Glucidic Metabolism in Women With PCOS and High Insulin Levels
|
Phase 1/Phase 2 | |
Completed |
NCT01675843 -
Ovarian Stimulation and Intrauterine Insemination in Women With Polycystic Ovarian Syndrome
|
Phase 4 | |
Completed |
NCT01577017 -
The Effects of Letrozole And Clomiphene Citrate For Induction of Ovulation In Polycystic Ovarian Syndrome(PCOS)
|
Phase 3 | |
Completed |
NCT00478504 -
Letrozole Versus Clomifene Citrate for Ovulation Induction
|
Phase 4 | |
Completed |
NCT05215223 -
Effect of Whole Body Vibration on Insulin Resistance in Females With Polycystic Ovarian Syndrome
|
N/A | |
Completed |
NCT03358199 -
LOD Before IVF/ICSI in PCOS Patients With High AMH
|
N/A | |
Completed |
NCT02436226 -
Use of Low Dose of HCG During Ovulation Induction With CC in Women With CC Resistant PCOS
|
Phase 4 |